NYSE:IQV - Iqvia Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$111.71 +0.60 (+0.54 %)
(As of 07/23/2018 01:33 PM ET)
Previous Close$111.60
Today's Range$111.17 - $112.13
52-Week Range$87.45 - $111.17
Volume51,139 shs
Average Volume1.22 million shs
Market Capitalization$22.92 billion
P/E Ratio25.55
Dividend YieldN/A
Beta0.62
Iqvia logoIQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
SymbolNYSE:IQV
CUSIPN/A
Phone203-448-4600

Debt

Debt-to-Equity Ratio1.22
Current Ratio1.16
Quick Ratio1.16

Price-To-Earnings

Trailing P/E Ratio25.55
Forward P/E Ratio22.03
P/E Growth1.86

Sales & Book Value

Annual Sales$9.74 billion
Price / Sales2.37
Cash Flow$9.8250 per share
Price / Cash11.37
Book Value$40.19 per share
Price / Book2.78

Profitability

EPS (Most Recent Fiscal Year)$4.36
Net Income$1.31 billion
Net Margins13.07%
Return on Equity13.35%
Return on Assets4.75%

Miscellaneous

Employees55,000
Outstanding Shares206,310,000
Market Cap$22,923.55

Iqvia (NYSE:IQV) Frequently Asked Questions

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) issued its quarterly earnings data on Wednesday, May, 2nd. The medical research company reported $1.34 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.27 by $0.07. The medical research company earned $2.56 billion during the quarter, compared to analyst estimates of $2.42 billion. Iqvia had a return on equity of 13.35% and a net margin of 13.07%. The business's revenue was up 34.1% compared to the same quarter last year. View Iqvia's Earnings History.

When is Iqvia's next earnings date?

Iqvia is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Iqvia.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia issued an update on its FY18 earnings guidance on Friday, May, 18th. The company provided EPS guidance of $5.20-5.45 for the period, compared to the Thomson Reuters consensus estimate of $5.40. The company issued revenue guidance of $10.05-10.25 billion, compared to the consensus revenue estimate of $10.15 billion.Iqvia also updated its Q2 guidance to $1.17-1.24 EPS.

What price target have analysts set for IQV?

18 brokerages have issued 1-year target prices for Iqvia's stock. Their forecasts range from $93.42 to $128.00. On average, they anticipate Iqvia's share price to reach $111.4953 in the next twelve months. This suggests that the stock has a possible downside of 0.4%. View Analyst Ratings for Iqvia.

What is the consensus analysts' recommendation for Iqvia?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 5 hold ratings, 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Iqvia's key competitors?

Who are Iqvia's key executives?

Iqvia's management team includes the folowing people:
  • Mr. Ari Bousbib, Chairman, CEO & Pres (Age 57)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 54)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 55)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 57)
  • Mr. James H. Erlinger III, Consultant (Age 60)

Has Iqvia been receiving favorable news coverage?

Media coverage about IQV stock has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Iqvia earned a coverage optimism score of 0.05 on Accern's scale. They also gave news articles about the medical research company an impact score of 44.62 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Iqvia's major shareholders?

Iqvia's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Hardman Johnston Global Advisors LLC (0.21%), Retirement Systems of Alabama (0.16%), Arvest Bank Trust Division (0.11%), Howard Capital Management (0.06%), Bank of Montreal Can (0.06%) and Fisher Asset Management LLC (0.05%). Company insiders that own Iqvia stock include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko and Robert Parks. View Institutional Ownership Trends for Iqvia.

Which major investors are selling Iqvia stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including Hardman Johnston Global Advisors LLC, Bank of Montreal Can, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Hartford Investment Management Co., Bremer Trust National Association, Fisher Asset Management LLC, Nisa Investment Advisors LLC and Westpac Banking Corp. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, Kevin C Knightly, Michael J Evanisko and Robert Parks. View Insider Buying and Selling for Iqvia.

Which major investors are buying Iqvia stock?

IQV stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Fjarde AP Fonden Fourth Swedish National Pension Fund, Clinton Group Inc., Cornerstone Wealth Management LLC, NN Investment Partners Holdings N.V., Ironsides Asset Advisors LLC, Gulf International Bank UK Ltd and Vision Capital Management Inc.. View Insider Buying and Selling for Iqvia.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $111.96.

How big of a company is Iqvia?

Iqvia has a market capitalization of $22.92 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. Iqvia employs 55,000 workers across the globe.

How can I contact Iqvia?

Iqvia's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 203-448-4600 or via email at [email protected]


MarketBeat Community Rating for Iqvia (NYSE IQV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  350 (Vote Outperform)
Underperform Votes:  303 (Vote Underperform)
Total Votes:  653
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.